A durable complete response resulting from treatment with nivolumab plus ipilimumab for metastatic collecting duct carcinoma of the kidney  

作　　者：Keisuke Funajima Sei Naito Takanobu Kabasawa Hayato Nishida Tomoyuki Kato Mitsuru Futakuchi Norihiko Tsuchiya 

机构地区：[1]Department of Urology,Yamagata University Faculty of Medicine,2-2-2 Iida-nishi,Yamagata,Japan [2]Department of Pathology,Yamagata University Faculty of Medicine,2-2-2 Iida-nishi,Yamagata,Japan

出　　处：《Asian Journal of Urology》2023年第3期376-378,共3页亚洲泌尿外科杂志（英文）

摘　　要：Dear Editor,Collecting duct carcinoma(CDC)or Bellini carcinoma originates in the distal collecting ducts.CDC is a markedly aggressive subtype of renal cell carcinoma and accounts for less than 1%of all renal cell carcinomas[1].We described a patient with CDC and psoriasis,who showed complete response(CR)after being treated with combination therapy of nivolumab and ipilimumab(NI).The study was conducted in accordance with and approved by the Ethics Committee of Yamagata University Faculty of Medicine(approval no.2019-35).The need for patient consent was waived by the same institutional review board;all the patients provided written informed consents.

关 键 词：markedly nivolumab APPROVAL 

分 类 号：R737.11[医药卫生—肿瘤]